Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496474 | 0.98 | MAPT (0.69) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL241358 | 0.94 | HDAC3 (0.67) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL297973 | 0.85 | KEAP1 (0.64) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL7065645 | 0.85 | MAPT (0.79) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| 5-Phenylvaleric Acid SCHEMBL27452259 | 0.83 | MAPT (0.92) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL3814880 | 0.83 | MAPT (0.83) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL9671779 | 0.83 | MAPT (0.83) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL7827144 | 0.81 | MAPT (0.80) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| 5-Phenylvaleric Acid SCHEMBL503601 | 0.81 | MAPT (0.96) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL11803736 | 0.80 | MAOA (0.40) | SLC6A3TBXAS1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| EP-1501897-B1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF SE (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7807836-B2 | Preparation of perylen-3,4:9,10-tetracarboxylic dianhydride and also of naphtalene-1,8-dicarboximides | BASF AKTIENGESELLSCHAFT (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080161569-A1 | PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | US | disclosed |
| US-7393956-B2 | Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20050131220-A1 | Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-16 | — | — | US | disclosed |
| EP-1501897-A1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091345-A1 | METHOD FOR THE PRODUCTION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIIMIDES AND PERYLEN-3,4:9,10-TETRACARBOXYLIC ACID DIANHYDRIDE AND NAPHTALENE-1,8-DICARBOXYLIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161569-A1 | PREPARATION OF PERYLEN-3,4:9,10-TETRACARBOXYLIC DIANHYDRIDE AND ALSO OF NAPHTALENE-1,8-DICARBOXIMIDES | CLIC1, PNPO, CLIC4 | MAPT 3106/4885RXFP1 4757/4885HDAC3 2294/4885 |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | MAPT 2115/4885RXFP1 3138/4885HDAC3 256/4885 |
| US-20050131220-A1 | Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides | CBR1, CBR3, SCO2 | MAPT 4153/4885RXFP1 2491/4885HDAC3 1051/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | MAPT 1986/4885RXFP1 2610/4885HDAC3 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.